Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Asterias Biotherapeutics
Menlo Park, California, United Statesasteriasbiotherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Asterias was conducting Phase 1/2a clinical trials for AST-OPC1 in spinal cord injury and VAC2 in non-small cell lung cancer. The company merged with BioTime in a transaction that was expected to be completed in Q1 2019.
- Therapeutic areas
- CardiovascularMetabolic DisordersRheumatologyOphthalmologyHematologyOncologyNeurology
- Modalities
- Cell therapyStem cell therapyImmunotherapyPluripotent stem cells
- Industry
- Biotech
02
Partnerships
California Institute for Regenerative Medicine (CIRM)Cancer Research UKWuchan Zhongda Geron
Beyond the preview
Go deeper on Asterias Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asterias Biotherapeutics.